Back to Clinical Trials
Phase 3Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Sponsored by Nuvalent Inc.

About this study

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).

Patients will be randomized in a 1:1 ratio (approximately 225 in each arm) to receive either neladalkib (NVL-655) or alectinib.

Where this study is enrolling (2)

  • Palo Verde Hematology Oncology

    Glendale, Arizona

    Call +1 602-978-6255

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

    I'm interested
Who can participate

Inclusion criteria

  • ✓1. Histologically or cytologically confirmed locally advanced (not amenable for multimodality treatment) or metastatic Non-small Cell Lung Cancer (NSCLC)
  • ✓2. Documented Anaplastic Lymphoma Kinase (ALK) rearrangement via testing of tissue or blood
  • ✓3. No prior systemic anticancer treatment for NSCLC (adjuvant/neoadjuvant chemotherapy allowed if 12 months prior to randomization; prior ALK tyrosine kinase inhibitor \[TKI\] such as alectinib is not allowed in any setting)
  • ✓4. Measurable disease (1 or more target lesions per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1)
  • ✓5. Pretreatment tumor tissue

Exclusion criteria

  • ✕1. Patient's cancer has a known oncogenic driver alteration other than ALK.
  • ✕2. Known allergy/hypersensitivity to excipients of neladalkib or alectinib.
  • ✕3. Ongoing or recent radiotherapy as per protocol-specified timeframes prior to randomization
  • ✕4. Major surgery within 4 weeks prior to randomization
  • ✕5. Uncontrolled clinically relevant infection requiring systemic therapy
  • ✕6. Known active tuberculosis, or active Hepatitis B or C
  • ✕7. QT corrected for heart rate by Fridericia's formula (QTcF) \> 470 msec on repeated assessments
  • ✕8. Clinically significant cardiovascular disease
  • ✕9. Brain metastases associated with progressive neurological symptoms or requiring increasing doses of corticosteroids to control CNS disease
  • ✕10. Active malignancy requiring therapy within 2 years prior to randomization

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.